Long-term Surival of GIST Patients ≥ 10 Years on Imatinib
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This is a cross-sectional cohort study of metastatic GastroIntestinal Stromal Tumor (GIST) patients on imatinib for ≥ 10 years included in EORTC trial 62005-STBSG entitled "Phase 3 randomized, intergroup, international tiral assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) expressing the KIT receptor tyrosine kinase (CD117) - NCT00685828". With this study, the aim is to identify patient characteristics, tumour characteristics, treatment factors and quality of life outcomes associated with prolonged treatment with imatinib and/or prolonged survival. This observational study will further help to put in place a questionnaire to evaluate patients quality of life with prolonged imatinib treatment, that will then be used in a prospective study.
Primary site [ Time Frame: 1 year from first patient in ]
Site of primary tumor (Oesophagus, cardia, stomach, duodenum, small intestine, colon, rectum, other, unknown)
Primary tumor grade [ Time Frame: 1 year from first patient in ]
Primary tumor grade according to mitoses (reported per 50 HPF or per 5 mm2)
Primary tumor stage [ Time Frame: 1 year from first patient in ]
Pirmary tumor stage in diameter (reported in cm)
Mutational status [ Time Frame: 1 year from first patient in ]
Mutational status of the primary tumor
Metastases [ Time Frame: 1 year from first patient in ]
Localisation of metastases
Previous systemic treatments [ Time Frame: 1 year from first patient in ]
Number of lines of previous systemic treatments
WHO performance status [ Time Frame: 1 year from first patient in ]
WHO performance status of patient at initiation of imatinib
Imatinib treatment [ Time Frame: 1 year from first patient in ]
Total duration of imatinib treatment
Response [ Time Frame: 1 year from first patient in ]
Best response during imatinib treatment according to RECIST1.1
Biospecimen Retention: Samples With DNA
First, existing data on molecular characteristics of included patients will be collected from the treating centers. If more than 40% of the data is not available, archival tumor tissue from patients enrolled in the EORTC 62005-STBSG study will be collected and used to identify molecular characteristics of the tumor that may predict long-term response to imatinib. Archival tumor tissues will be retrieved from the central lab of the study 62005-STBSG (UZ Leuven, Belgium) or from the sites (if applicable).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
28 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients enrolled in the 62005 trial - treated for more than 10 years with imatinib - will be enrolled in this study.
Patients included in the EORTC 62005 trial: Adult patients with metastasized GIST
Patients who have been treated with imatinib for ten years or longer